lipolysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-22. Numbers and descriptions here follow the published literature rather than marketing material.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
== Acquisition == The company is currently being acquired by NYSE-listed health and wellness company, Hims & Hers Health in a deal worth US$1.15 billion (AU$1.6 billion). The acquisition includes a US$240 million (AU$340 million) payment when the deal closes, then deferred payments in cash or stock over the following 18 months, plus additional earn-out payments based on financial targets until 2029. Eucalyptus is also known to have an employee-friendly equity term. The value of employee shares under the deal, excluding its co-founders, is approximately AU$300 million. The average employee participant is expected to receive AU$420,000. Co-founder and CEO Tim Doyle, will become the SVP of international operations at Hims & Hers.
Dichloroacetylene (DCA) is an organochlorine compound with the formula C2Cl2. It is a colorless, pyrophoric, explosive liquid that has a sweet and "disagreeable" odor. Dichloroacetylene is neurotoxic, hepatotoxic, nephrotoxic and possibly carcinogenic.
==== Anabolic ==== Bone marrow stimulation: For decades, AAS were the mainstay of therapy for hypoplastic anemias due to leukemia, kidney failure or aplastic anemia. Growth stimulation: AAS can be used by pediatric endocrinologists to treat children with growth failure. However, the availability of recombinant growth hormone, which has fewer side effects, makes this a secondary treatment. Stimulation of appetite and preservation and increase of muscle mass: AAS have been given to people with chronic wasting conditions such as cancer and AIDS. Stimulation of lean body mass and prevention of bone loss in elderly men, as some studies indicate. However, a 2006 placebo-controlled trial of low-dose testosterone supplementation in elderly men with low levels of testosterone found no benefit on body composition, physical performance, insulin sensitivity, or quality of life. Prevention or treatment of osteoporosis in postmenopausal women. Nandrolone decanoate is approved for this use. Although they have been indicated for this treatment, AAS saw little use for this purpose due to their virilizing side effects. Aiding weight gain following surgery or physical trauma, during chronic infection, or in the context of unexplained weight loss. Counteracting the catabolic effect of long-term corticosteroid therapy. Oxandrolone improves both short-term and long-term outcomes in people recovering from severe burns, and is well-established as a safe treatment for this indication. Treatment of idiopathic short stature, hereditary angioedema, alcoholic hepatitis, and hypogonadism.
== Independent evaluation of the software == CASMI (Critical Assessment of Small Molecule Identification) is an open contest on the identification of small molecules from mass spectrometry data, and was launched in 2012 by Emma Schymanski and Steffen Neumann. In CASMI 2016, CSI:FingerID and a derivative of CSI:FingerID, in which the Böcker Group was also involved, won first and second place in the category "Best Automatic Structural Identification - In Silico Fragmentation Only". Also, CSI:FingerID had the best result for ranking the correct molecule structure at position one (70 out of 127, positive mode). In CASMI 2017, SIRIUS plus CSI:FingerID won in 3 of 4 categories: "Best Structure Identification on Natural Products", "Best Automatic Structural Identification - In Silico Fragmentation Only", "Best Automatic Candidate Ranking". In CASMI 2022, six out of 16 contestants used SIRIUS in their workflow to identify the best molecular structure candidates. SIRIUS won in the categories "Correct elemental formulas", "Correct compound structure classes" and "Correct 2D chemical structures". CASMI 2022 included compounds that were not even contained in PubChem.
Sources: en.wikipedia.org
14 August – Police are investigating the deaths of two 18-year-olds who attended an event at Glasgow's SWG3 venue. 16 August – Junior doctors in Scotland have voted to accept a pay offer from the Scottish Government worth 4.5% for 2022–23 and 12.4% for 2023–24. 17 August – GMB Scotland announces that non-teaching staff in ten Scottish council areas will stage two days of strike action on 13 and 14 September. The Scottish Parliament plays host to Comedy Unleashed, starring Father Ted creator Graham Linehan, after the show is cancelled by two venues in Edinburgh. Carnbooth House, a listed building and former hotel in Glasgow, is destroyed by fire. 22 August – Broadcaster Nicky Campbell gives evidence to the Scottish Child Abuse Inquiry, where he alleges that a teacher who worked at two Edinburgh schools abused children on a "Savile scale". 23 August – Murray Foote is appointed as the SNP's new chief executive, replacing Peter Murrell. 25 August – Alexander McKellar, who killed a cyclist on a remote road in the Scottish Highlands while drink driving in September 2017 and then hid the body, is sentenced to 12 years in prison. Members of Unison in 24 of Scotland's 32 council areas vote to take industrial action after rejecting a 5.5% pay offer. 26 August – A search for the Loch Ness Monster, described as the largest in 50 years, gets underway both in the vicinity of Loch Ness itself, and through an online stream of the loch. A group of people looking for the creature subsequently claim to have heard sounds, but fail to record anything.
=== Niche uses === Triethylamine is commonly used in the production of anionic polyurethane dispersions (resins dispersed in water rather than solvents) as a neutralizing agent. Triethylamine is used to give salts of various carboxylic acid-containing pesticides, e.g. Triclopyr and 2,4-dichlorophenoxyacetic acid. Triethylamine is the active ingredient in FlyNap, a product for anesthetizing fruit flies. It is also used in mosquito and vector control labs to anesthetize mosquitoes. This is done to preserve any viral material that might be present during species identification. The bicarbonate salt of triethylamine (often abbreviated TEAB, triethylammonium bicarbonate [(CH3CH2)3NH]+HCO−3) is useful in reverse phase chromatography, often in a gradient to purify nucleotides and other biomolecules. Triethylamine was discovered by the Germans during the early 1940s to be hypergolic in combination with nitric acid, and was used as a component in the German Wasserfall rocket. The Soviet Scud missile used TG-02, a mixture of 50% xylidine and 50% triethylamine as a starting fluid to ignite its rocket engine.
However, this method is not truly analogous to protein structural alignment techniques because it computationally predicts the structures of the RNA input sequences rather than requiring experimentally determined structures as input. Although computational prediction of the protein folding process has not been particularly successful to date, RNA structures without pseudoknots can often be sensibly predicted using free energy-based scoring methods that account for base pairing and stacking.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.